(From left to right) Mr Rio Lee, Chief Transformation Officer, Gleneagles Hospital Hong Kong; Mr Albert Wong, Former Chief Executive Officer of Hong Kong Science & Technology Parks Corporation; Mr Paul Lau, Regional Chief Financial Officer of IHH Healthcare North Asia and Chief Financial Officer of Gleneagles Hospital Hong Kong; Dr Kenneth Tsang, Regional Chief Executive Officer, IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong; Professor Liu Hongbin, Director of the Centre for Artificial Intelligence and Robotics, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences (CAIR); Dr Jun Xu, Senior Director of Business Development, CAIR; Mr Haihong Zhang, Senior Director of AI Products, CAIR; Ms Lehan He, Director of Commercial Strategy, CAIR

(24 March 2026 – Hong Kong) Gleneagles Hong Kong, a member of the IHH Healthcare multinational network, yesterday (23 March) signed a collaboration agreement with the Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, to jointly advance the research, testing and application of artificial intelligence (AI) and robotics technologies in healthcare, with the aim of accelerating the development of patient‑centred smart healthcare.

Committed to promoting healthcare innovation, Gleneagles Hong Kong works closely with various technology partners to develop and apply solutions that enhance service quality, operational efficiency and the overall patient experience. The collaboration agreement marks Gleneagles Hong Kong as CAIR’s first local private healthcare strategic partner. Under this collaboration, the two parties will focus on six key thematic areas, including: the use of large‑model and robotics technologies to support ultrasound image acquisition and analysis; medical consultation chatbots to assist patients with preliminary risk assessment and specialty triage before and after clinical visits, and to enable seamless integration with hospital or clinic appointment systems; AI‑driven optimisation of inpatient and outpatient workflows through the redesign of clinical processes, service orchestration and enhanced digital experiences; AI‑assisted diagnostic support for medical imaging such as X‑ray, computed tomography (CT) and magnetic resonance imaging (MRI); AI‑driven screening, monitoring and analysis for liver fibrosis; and medical simulation for education, supporting clinicians in areas such as surgical planning, patient communication and multidisciplinary collaboration.

Hospital, medical and ambulatory care centres and clinics under Gleneagles Hong Kong network will serve as real‑world clinical settings for piloting and evaluating new technologies and solutions. Within this collaboration framework, both parties will jointly define detailed technical requirements, clinical validation plans and pilot programmes for individual initiatives, ensuring that technology applications are safe, reliable and aligned with clinical needs.

Dr Kenneth Tsang, Regional Chief Executive Officer, IHH Healthcare North Asia, and Chief Executive Officer of Gleneagles Hospital Hong Kong, said, “As a key member of IHH Healthcare in North Asia, Gleneagles Hong Kong has long upheld the Group’s commitment to advancing smart healthcare by actively leveraging cutting‑edge innovations to deliver future‑ready healthcare services. Through this collaboration with CAIR, we are honoured to contribute to the advancement of medical technology by bringing together research and clinical expertise. This partnership will help accelerate the translation of AI and robotics research outcomes into real‑world clinical applications, while also aligning with the government’s policy direction of promoting AI+ and industry integration. We hope this collaboration will further strengthen Hong Kong’s smart healthcare ecosystem, drive regional development, and support the international expansion of medical technologies developed in the Mainland across the IHH’s multinational healthcare network.” 

CAIR is a research institute established in Hong Kong by the Chinese Academy of Sciences and is located at the Hong Kong Science Park. It is also one of the research centres under the Government’s InnoHK innovation platform. CAIR actively collaborates with local and global universities, >span class="NormalTextRun SCXW169561488 BCX0"> and enterprises, with the aim of achieving breakthroughs in artificial intelligence and robotics technologies and supporting innovation and technology development in the Greater Bay Area.

Professor Liu Hongbin, Director of the Centre for Artificial Intelligence and Robotics,  Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, said, “CAIR has always been committed to developing internationally competitive artificial intelligence and robotics technologies. We are pleased to collaborate with Gleneagles Hong Kong to extend our research outcomes into real clinical settings. Through joint validation and applied research, this partnership will help accelerate the adoption and implementation of advanced technologies in real‑world healthcare environments. We look forward to working together to promote the long‑term development of smart healthcare in Hong Kong and the region.” 

Looking ahead, Gleneagles Hong Kong and CAIR will continue to combine their respective strengths in research and clinical practice, focusing on innovation driven by patient well‑being, and jointly explore AI and robotics healthcare solutions with long‑term development potential, injecting new momentum into Hong Kong’s smart healthcare innovation ecosystem.